NEUVOGEN, Inc.

NEUVOGEN is a San Diego-based biotechnology company specializing in the development of next-generation therapeutic whole-cell cancer vaccines. The company utilizes a proprietary systems-based approach to engineer off-the-shelf vaccines that express a broad array of tumor-associated and tumor-specific antigens, aiming to activate the patient's immune system to target solid tumors, prevent relapse, and treat micrometastases. The company's platform is designed for scalability and ease of integration into standard clinical settings, distinguishing it from more complex, patient-specific cell therapies. By leveraging advanced bioinformatics and genetic engineering, NEUVOGEN seeks to overcome the heterogeneity of solid tumors and provide a more accessible, cost-effective immunotherapy option for patients.